08/10/2026 01:36
Sangfor aSV Now Supported by Veeam Backup & Replication 13.1

Sangfor Technologies, a global provider of cybersecurity, cloud computing, and IT infrastructure solutions, is proud to announce that Sangfor aSV, the native hypervisor engine powering Sangfor HCI, is now supported by Veeam Backup & Replication 13.1 through a dedicated Veeam plug-in. The integration enables organizations to protect workloads running on Sangfor HCI directly within the Veeam environment, delivering a unified backup and recovery experience. As organizations evaluate VMware...

08/10/2026 03:49
Ant International’s Bettr Partners with Muslim Pro to Introduce Umrah Financing Service in Malaysia

Bettr, a leading provider of inclusive and embedded finance and fintech solutions under Ant International, today announced its partnership with Muslim Pro, a popular Islamic lifestyle app serving over 190 million downloads worldwide, to launch an Umrah financing solution in Malaysia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260809780047/en/Ant International's Bettr and Muslim Pro launch an Umrah financing solution in Malaysia ...

08/10/2026 06:00
OpenGate Capital to Acquire Maersk Training, the Global Safety Training and Gas-Safety Services Business of Maersk

OpenGate Capital (“OpenGate”), a global private equity firm, announced today that it has signed a definitive agreement to acquire Maersk Training and its subsidiary Maersk H2S Safety Services. The company, a provider of global safety training and gas safety services, is being carved out from A.P. Møller - Mærsk A/S (MAERSK A:CPH), a listed integrated logistics company. Headquartered in Svendborg, Denmark, Maersk Training is a leading global provider of essential safety services that operates ...

08/10/2026 10:00
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncology assets from BeOne with any of Revolution Medicines’ four clinical RAS(ON) inhibitors, and a separate...